ASCO Publishes Abstracts for Alnylam, Silence Cancer Drugs

The abstracts provided quick glimpses of new phase I data on the companies' respective siRNA-based cancer drugs, showing that both are well-tolerated and providing hints about their possible efficacy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.